mobihealthnews.com·May 14, 2026
Isomorphic Labs, an AI drug discovery company, secured $2.1 billion in Series B funding led by Thrive Capital, with support from existing and new investors including Alphabet, GV, and the UK Sovereign AI Fund.
Isomorphic Labs' successful $2.1 billion Series B funding round, including backing from major investors such as Alphabet, Google Ventures, and new entrants like MGX and the UK Sovereign AI Fund, signals a strong investment interest in AI-driven drug discovery. This development highlights the growing confidence in AI's potential to revolutionize drug development, suggesting that there could be significant opportunities for growth and partnerships in this sector.